Abstract
A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Analgesics, Opioid / adverse effects
-
Analgesics, Opioid / blood
-
Analgesics, Opioid / pharmacokinetics*
-
Drug Interactions
-
Female
-
HIV Infections / drug therapy
-
HIV Protease Inhibitors / pharmacology*
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Lopinavir
-
Male
-
Methadone / adverse effects
-
Methadone / blood
-
Methadone / pharmacokinetics*
-
Opioid-Related Disorders / etiology
-
Pyrimidinones / pharmacology
-
Pyrimidinones / therapeutic use
-
RNA, Viral / drug effects
-
Ritonavir / pharmacology
-
Ritonavir / therapeutic use
-
Substance Withdrawal Syndrome / etiology*
Substances
-
Analgesics, Opioid
-
HIV Protease Inhibitors
-
Pyrimidinones
-
RNA, Viral
-
Lopinavir
-
Ritonavir
-
Methadone